

557405

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)


PCT

(10) International Publication Number
WO 2004/092201 A2


- (51) International Patent Classification⁷: **C07K** **HUMAN SERVICES [US/US]; 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (US).**
- (21) International Application Number: PCT/US2004/009617
- (22) International Filing Date: 29 March 2004 (29.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/459,507 31 March 2003 (31.03.2003) US
- (71) Applicant (for all designated States except US): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND**
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **BERZOFSKY, Jay, A. [US/US]; 5908 Bradley Blvd., Bethesda, Maryland 20814-1107 (US). OKAZAKI, Takahiro [JP/JP]; C-2 Fujishirohaisu, 698-7 Ohbacho, Aobaku, Yokohama 225-0023 (JP).**
- (74) Agents: **GAO, Chuan et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, California 94111 (US).**
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

[Continued on next page]

(54) Title: **ENHANCED HIV-1 VACCINES AND METHODS FOR THEIR USE**



(57) Abstract: **ENHANCED HIV-1 VACCINES AND METHODS FOR THEIR USE ABSTRACT** The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine.



WO 2004/092201 A2



KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.